Gilead Sciences filings document material events, operating results, governance matters and capital-structure disclosures for a Delaware biopharmaceutical company whose common stock trades as GILD on the Nasdaq Global Select Market. Form 8-K reports furnish quarterly and annual financial results, including GAAP and non-GAAP measures and reconciliations, and disclose completed acquisition activity affecting oncology pipeline assets.
Proxy and annual meeting filings record director elections, auditor ratification and shareholder voting outcomes. Other current reports cover executive and governance changes, Regulation FD disclosures, material agreements, and formal exhibits tied to Gilead’s virology and oncology business, including clinical or regulatory disclosure categories when they are part of the company’s public reporting.
Gilead Sciences (GILD) Form 144 notice records a proposed sale of 3,000 common shares via Morgan Stanley Smith Barney for an aggregate market value of $340,710, with an approximate sale date of 09/15/2025 on NASDAQ. The shares were acquired as performance shares on 01/31/2024. The filing also discloses that Johanna Mercier sold 34,000 shares across three transactions in the past three months (06/16/2025, 07/15/2025, 08/15/2025) generating total gross proceeds of $3,982,524.65. The filer affirms no undisclosed material adverse information and the notice is presented as a live filing.
Daniel P. O'Day, Gilead Sciences, Inc. Chairman & CEO, reported stock award and a sale on Form 4. He received 10,427 restricted stock units (RSUs) on 09/10/2025; each RSU converts to one share and the grant follows a four-year vesting schedule with 25% vesting after one year and the remainder vesting 6.25% quarterly thereafter. The filing also shows a disposition of 4,949 shares on 09/10/2025 at a price of $115.25 per share. After these transactions the filing reports 601,203 shares beneficially owned directly and 98,496 RSUs outstanding.
Gilead Sciences insider Diane E. Wilfong, identified as Interim Corporate Controller & CAO, reported transactions on 09/10/2025. She was credited with 921 restricted stock units (RSUs) that represent rights to 921 shares subject to a four-year vesting schedule (25% at year one, then 6.25% quarterly). The filing also shows a disposition of 338 shares at a price of $115.25 each. After the transactions, Ms. Wilfong directly beneficially owns 46,259 common shares and holds 7,864 RSUs outstanding. The Form 4 is signed by power of attorney on 09/11/2025.
Deborah H. Telman, Executive Vice President, Corporate Affairs & General Counsel of Gilead Sciences (GILD), reported two transactions on 09/10/2025. She was granted 1,315 restricted stock units (RSUs), each converting to one share, which vest over four years (25% at year one, then 6.25% quarterly). The RSU grant increased contingent ownership by 1,315 shares. On the same date she disposed of 634 shares in a sale at $115.25 per share. After these transactions she beneficially owned 43,402 shares (44,036 including the unvested RSUs). The Form 4 was signed by power of attorney on her behalf.
Gilead Sciences (GILD) Form 4 filed for Johanna Mercier, Chief Commercial Officer. The filing reports on 09/10/2025 the grant of 3,844 restricted stock units (RSUs), each representing the right to one share, and the sale/disposition of 1,819 shares at $115.25 per share. After these transactions Mercier beneficially owned 116,193 shares on a direct basis. The RSUs carry a four-year vesting schedule with 25% vesting at the first anniversary and the remainder vesting quarterly at 6.25% until fully vested. The Form 4 is signed by an authorized power of attorney on behalf of the reporting person.
Gilead Sciences insider transactions by CFO Andrew D. Dickinson: The filing shows a grant of 3,696 restricted stock units (RSUs) on 09/10/2025, each convertible into one share and subject to a four-year vesting schedule (25% at one year, then 6.25% quarterly). The filing also reports a sale of 1,751 shares on 09/10/2025 at $115.25 per share. After these transactions, Mr. Dickinson beneficially owned 162,055 shares directly and had 3,696 RSUs outstanding, representing 31,219 total shares when combining vested holdings and unvested RSUs.
Daniel P. O'Day, Chairman & CEO and director of Gilead Sciences, reported a sale of 10,000 shares of GILD common stock on 08/28/2025 at a price of $113.63 per share. After the reported sale, Mr. O'Day beneficially owned 595,725 shares. The filing states the sale was made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025, and the Form 4 was signed by Edward S. Son by power of attorney on 08/29/2025. The document contains no additional transactions, derivatives, or explanatory financial data beyond these disclosure items.
Form 144 filing for Gilead Sciences (GILD) reports proposed and recent insider sales of common stock by Daniel O'Day. The filing shows an intended sale of 10,000 shares through Morgan Stanley Smith Barney on NASDAQ with an aggregate market value of $1,136,300 and an approximate sale date of 08/28/2025. The shares were originally acquired as restricted stock on 03/01/2022. The filer also reported three recent sales by the same person: 10,000 shares on 07/28/2025 for $1,139,369, 10,000 shares on 06/30/2025 for $1,104,483, and 10,000 shares on 05/30/2025 for $1,104,192. The filing lists 1,240,806,916 shares outstanding.
Johanna Mercier, Chief Commercial Officer of Gilead Sciences (GILD), reported multiple transactions on 08/15/2025 executed under a Rule 10b5-1 trading plan adopted Feb 20, 2025. The filing shows a series of option-related acquisitions and open-market sales in common stock: total reported sales on that date equal 28,000 shares at prices ranging roughly from $117.91 to $119.01, and multiple option exercises/acquisitions at an exercise price of $66.64. Following the reported transactions, the filing lists beneficial ownership levels of common stock as low as 114,168 shares and various counts of options/derivatives remaining outstanding. The Form 4 also discloses that the related options have a four-year vesting schedule with 25% vesting after one year and the remainder vesting quarterly thereafter.
Andrew D. Dickinson, Chief Financial Officer of Gilead Sciences (GILD), reported an insider sale on Form 4. The filing shows a sale of 2,500 shares of Gilead common stock on 08/15/2025 at a price of $118.53 per share, leaving Mr. Dickinson with 160,110 shares beneficially owned after the transaction. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on 08/29/2024. The Form 4 was signed by Edward S. Son by power of attorney for Mr. Dickinson and dated 08/18/2025.